Home Merck Announces Settlement and License Agreement Resolving KEYTRUDA (pembrolizumab) Patent Litigation
 

Keywords :   


Merck Announces Settlement and License Agreement Resolving KEYTRUDA (pembrolizumab) Patent Litigation

2017-01-20 22:01:00| Merck.com - Corporate News

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd., resolving the worldwide patent infringement litigation related to the use of an anti-PD-1 antibody for the treatment of cancer, such as KEYTRUDA (pembrolizumab). Language: English Contact: Merck Media: Pamela Eisele, 267-305-3558Claire Gillespie, 267-305-0932or Investors: Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: agreement license patent settlement

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11 EVA 6
24.11 8
24.11SEVENTEEN ALWAYS YOURS Weverse 13
24.11 DX
24.11 No.23/1998
24.11 DVD 9
24.11
24.11 CD His Melody
More »